This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Birth asphyxia occurs in 3-9 of every 1000 live-born infants and accounts for 23% of neonatal deaths globally. Thirty to forty percent of the survivors are left with severe and life-long neurodevelopmental handicaps. No safe and effective treatments are available to treat this problem. Although some damage occurs acutely during an asphyxial event, much of the injury to the neonatal brain occurs in the hours immediately following the event. Thus an intervention during the hours following injury may effectively decrease the ongoing brain damage. One promising treatment is high dose erythropoietin (Epo). Epo treatment up to 6 hours following brain injury can reduce the brain damage caused by asphyxia, hemorrhage, or trauma by 50-70%.
The specific aims of this project are to develop a non-human primate model of perinatal asphyxia in which to test neuroprotective strategies. We will specifically test the safety and efficacy of high dose Epo in newborn pigtailed macaques that have undergone perinatal asphyxia.
Showing the most recent 10 out of 320 publications
